Drug Trial Radar · NCT03983980
Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)
Last checked: Nov 20, 2026Latest source record: Jun 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
515
Actual
Start
Jun 6, 2019
Primary completion
May 13, 2020
Study completion May 29, 2020
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- Collaborators
- IQVIA Biotech
- First posted
- Jun 12, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized double-blind vehicle-controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% once daily for the treatment of plaque psoriasis in adults. Approximately 500 adult subjects with plaque psoriasis will be randomized 2:1 to receive either tapinarof cream, 1% or matching vehicle cream once daily for 12 weeks.
Conditions
- Plaque Psoriasis
Interventions
TapinarofDrug
Tapinarof cream, 1%, applied once daily
Vehicle CreamDrug
Vehicle cream applied once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple ImputationTime frame: Baseline to Week 12
Locations
50 sites in 2 countries. Site status is shown where the registry gives one.
Dermavant Investigative Site
Fort Smith, Arkansas
Dermavant Investigative Site
Fountain Valley, California
Dermavant Investigative Site
Fremont, California
Dermavant Investigative Site
Los Angeles, California
Dermavant Investigative Site
Oceanside, California
Dermavant Investigative Site
San Diego, California
Dermavant Investigative Site
Santa Monica, California
Dermavant Investigative Site
Denver, Colorado
Dermavant Investigative Site
Boynton Beach, Florida
Dermavant Investigative Site
Margate, Florida
Dermavant Investigative Site
Miami, Florida
Dermavant Investigative Site
Boise, Idaho
Dermavant Investigative Site
Rolling Meadows, Illinois
Dermavant Investigative Site
Plainfield, Indiana
Dermavant Investigative Site
Overland Park, Kansas
Dermavant Investigative Site
Louisville, Kentucky
Dermavant Investigative Site
Owensboro, Kentucky
Dermavant Investigative Site
Metairie, Louisiana
Dermavant Investigative Site
Boston, Massachusetts
Dermavant Investigative Site
Bay City, Michigan
Dermavant Investigative Site
Detroit, Michigan
Dermavant Investigative Site
Fort Gratiot, Michigan
Dermavant Investigative Site
Fridley, Minnesota
Dermavant Investigative Site
Omaha, Nebraska
Dermavant Investigative Site
Las Vegas, Nevada
Dermavant Investigative Site
East Windsor, New Jersey
Dermavant Investigative Site
Hackensack, New Jersey
Dermavant Investigative Site
Stony Brook, New York
Dermavant Investigative Site
Wilmington, North Carolina
Dermavant Investigative Site
Winston-Salem, North Carolina
Dermavant Investigative Site
Beachwood, Ohio
Dermavant Investigative Site
Bexley, Ohio
Dermavant Investigative Site
Portland, Oregon
Dermavant Investigative Site
Charleston, South Carolina
Dermavant Investigative Site
Nashville, Tennessee
Dermavant Investigative Site
Houston, Texas
Dermavant Investigative Site
Pflugerville, Texas
Dermavant Investigative Site
Plano, Texas
Dermavant Investigative Site
San Antonio, Texas
Dermavant Investigative Site
Webster, Texas
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.